secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001437749-25-038313
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places Cassava's simufilam TSC-related epilepsy trial on full clinical hold; initiation delayed beyond H1 2026
--------------------------------------------------------------------------------

- FDA letter on Dec 15, 2025 places proposed simufilam TSC-related epilepsy trial on full clinical hold.
- Company must provide additional pre-clinical data and modify the protocol design to address FDA's items.
- Initiation of proof-of-concept trial no longer expected in first half of 2026; revised timing depends on FDA review.
- Cassava intends to work expeditiously to satisfy FDA's information requests but offers no new timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925038313/0001437749-25-038313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925038313/sava20251218_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer